Difficulty: Medium
Correct Answer: Trace, low–molecular-mass antigens such as drugs and hormones
Explanation:
Introduction / Context:
Immunoassay formats include competitive and noncompetitive (sandwich) designs. Selecting the appropriate format depends on antigen size, valency, and available epitopes. Competitive assays are the historical backbone of drug screening and hormone quantification at picomolar to nanomolar levels.
Given Data / Assumptions:
Concept / Approach:
In a competitive format, sample analyte competes with a labeled analyte or coated analog for a limited amount of antibody binding sites. This design excels when the target is too small for a two-site capture–detection scheme and when very low concentrations must be detected with high specificity.
Step-by-Step Solution:
Classify analyte by size and epitope count: drugs and many hormones are small and monovalent.Map to assay choice: competitive immunoassay is ideal for small haptens at trace levels.Select the option explicitly referencing trace drugs and hormones.
Verification / Alternative check:
Toxicology screens and doping tests routinely use competitive ELISA or RIA for analytes like cortisol, thyroxine, and therapeutic drugs.
Why Other Options Are Wrong:
High-abundance proteins are better quantified by sandwich assays. T-cell enumeration is a cellular analysis, not an antibody competition assay. Detecting live bacteria “without antibodies” is not an immunoassay. Competitive assays are not exclusive to IgE measurement.
Common Pitfalls:
Misinterpreting the inverse signal–concentration relationship; failing to include proper standard curves for quantitation.
Final Answer:
Trace, low–molecular-mass antigens such as drugs and hormones.
Discussion & Comments